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Abstract Increased and decreased methylation at specific
sequences (hypermethylation and hypomethylation, respec-
tively) is characteristic of tumor DNA compared to normal
DNA and promotes carcinogenesis in multiple ways including
genomic instability. Long interspersed element (LINE), an
abundantclassofretrotransposons,providesasurrogatemarker
for global hypomethylation. We developed methylation-
specific multiplex ligation-dependent probe amplification
assays to study LINE-1 methylation in cases of colorectal,
gastric, and endometrial cancer (N0276), stratified by patient
category [sporadic; Lynch syndrome (LS); familial colorectal
cancer type X (FCCX)] and microsatellite instability status.
Within each patient group, LINE-1 showed lower methylation
in tumor DNA relative to paired normal DNA and hypomethy-
lation was statistically significant in most cases. Interestingly,
normal colorectal mucosa samples from different patient
groups displayed differences in LINE-1 methylation that mir-
rored differences between the respective tumor tissues, with a
decreasing trend for LINE-1 methylation from patients with
sporadic colorectal cancer to LS to FCCX. Despite the fact that
the degree of LINE-1 methylation is generally tissue specific,
normal colorectal mucosa, gastric mucosa, and endometrium
from LS patients showed similar levels of LINE-1 methylation.
Our results suggest that the degree of LINE-1 methylation may
constitute a “field defect” that may predispose normal tissues
for cancer development.
Keywords LINE-1.DNAmethylation.Hereditarycancer.
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Introduction
Methylation of cytosine residues at CpG dinucleotides is a
major epigenetic modification in human cells, and 70–80%
ofalldinucleotides are heavily methylated[1].Thisistrue,for
example, for transposable elements such as long interspersed
elements (LINEs), which constitute 17% of the human ge-
nome being present at over 500,000 copies [2]. Regions that
are generally free of methylated CpG dinucleotides include
the so-called CpG islands, which are around 1-kb stretches of
DNA with high GC content enriched in promoter regions of
genes [3]. Approximately 27,000 CpG islands have been
identified in the nonrepetitive portion of the human genome
[4]. In contrast to normal cells, cancer cells often show recip-
rocal hypermethylation of CpG islands [CpG island methyl-
ator phenotype (CIMP)] along with a global decrease in 5-
methylcytosine content in the remainder of the genome [5].
The full-length LINE-1 element is 6 kb long and includes
molecular machinery that allows retrotransposition. Most
LINE-1 copies have become inactive over time as a result
of truncations and mutations; some 4,000 remain full length
and up to 100 copies may be functional [6, 7]. Ongoing
LINE-1 retrotransposition is a prominent source of interin-
dividual genetic variation [7] and an important cause of
human genetic disease [8]. In cancer, DNA hypomethylation
can result in LINE-1 activation and consequent retrotrans-
position throughout the genome leading to disruption of
genes and chromosomal instability (CIN) [9]. Moreover,
an activated LINE-1 promoter can initiate sense or antisense
transcription through other genes [2, 6]. The methylation
status of retrotransposons may also contribute to the long-
Electronic supplementary material The online version of this article
(doi:10.1007/s00109-011-0854-z) contains supplementary material,
which is available to authorized users.
W. Pavicic: E. I. Joensuu:T. Nieminen: P. Peltomäki (*)
Department of Medical Genetics, Haartman Institute,
University of Helsinki,
Helsinki, PO Box 63, 00014, Finland
e-mail: paivi.peltomaki@helsinki.fi
J Mol Med (2012) 90:827–835
DOI 10.1007/s00109-011-0854-zrange epigenetic control of activity of neighboring genes
[10].
Like CpG island methylation, LINE-1 hypomethylation
can occur early in tumorigenesis. Ibrahim et al. [11] showed
a decrease in LINE-1 methylation from normal mucosa to
adenoma (statistically nonsignificant) and from adenoma to
carcinoma (significant). Park et al. [12] found a progressive
decrease of LINE-1 methylation from chronic gastritis to
intestinal metaplasia to gastric adenoma to gastric cancer.
Moreover, LINE-1 hypomethylation in tumors may be as-
sociated with familial cancer [13, 14], and blood levels of
LINE-1 methylation may be associated with increased can-
cer risk [15] and/or familial cancer [16], suggesting a pos-
sible role of LINE-1 methylation in familial or hereditary
cancer. Prompted by these findings, we undertook an inves-
tigation to examine the levels of LINE-1 methylation in
normal and cancer tissues from individuals with familial/
hereditary cancers and their sporadic counterparts, stratified
by microsatellite instability (MSI) status. Familial/heredi-
tary cancers included Lynch syndrome (LS), a multi-organ
cancer syndrome due to inherited mutations in DNA mis-
match (MMR) genes, and familial colorectal cancer, type X
(FCCX), referring to familial nonpolypotic colorectal cancer
without MMR defects. For LINE-1 methylation analysis, a
novel assay based on methylation-specific multiplex
ligation-dependent probe amplification (MS-MLPA) was
developed and validated to facilitate studies on formalin-
fixed paraffin-embedded (FFPE) samples.
Materials and methods
Patients and samples
LINE-1 methylation was investigated in 276 tumors and
corresponding normal tissue samples, consisting of 168
colorectal carcinomas (CRC), 58 gastric carcinomas (GC,
41 of which were intestinal and 17 diffuse), and 50 endo-
metrial carcinomas (EC) (Table 1). All human studies were
approved by the appropriate institutional review boards of
the Helsinki University Central Hospital. Samples were
previously characterized for MSI status and MMR protein
expression [17–20]. Germline mutation status stratified the
cases into LS (Lynch syndrome with germline mutations in
MSH2, MLH1,o rMSH6), FCCX (familial nonpolypotic
CRC without MMR gene mutations), and sporadic cases
(the latter were divided into microsatellite-stable, MSS,
and microsatellite-unstable, MSI, subgroups). DNA was
extracted from FFPE tumor blocks from selected areas with
high tumor percentages and matching normal tissue by a
method modified from Isola et al. [21]. Additionally, seven
commercial cell lines (HCT116, HCT15, HCA7, RKO,
KM12, HEC59, and K-562), one sample from a healthy
individual, and one unmethylated control sample, which
was generated using a GenomePlex complete whole genome
amplification (WGA) kit (Sigma-Aldrich Chemie Gmbh,
Germany) [22] were used to compare MS-MLPA and com-
bined bisulfite restriction analysis (COBRA).
Custom-made MS-MLPA for LINE-1
In MS-MLPA [23], a signal peak is generated if sample
DNA is methylated because methylation protects DNA-
probe hybrids against digestion by the methylation-
sensitive enzyme HhaI (cuts at GCGC), and the ligated
probes can be amplified by the polymerase chain reaction.
For custom-made MS-MLPA design, three areas inside the
LINE-1 promoter sequence (with an HhaI site), and seven
more regions, located in the remaining portion of the LINE-
1 element (without HhaI recognition sequence), were cho-
sen, and a specific MS-MLPA probe pair was created for
each, giving rise to the so-called “L1-m probes” and “con-
trol probes,” respectively (see Table 2 and Fig. 1). A pub-
lished sequence for L1.2 (GenBank accession no. M80343,
http://www.ncbi.nlm.nih.gov/nuccore/339773) was used.
For the synthetic MS-MLPA probe design, the manufacturer’s
instructions (http://www.mrc-holland.com) were followed.
An MS-MLPA probe pair consists of two oligonucleotides,
the left probe oligonucleotide (LPO) and the right probe
oligonucleotide (RPO). Custom-made MS-MLPA probes
(Table 2), including seven control probes and three
methylation-sensitive probes were combined to make a com-
plete MS-MLPA assay (LINE-1-MS-MLPA kit). MS-MLPA
reaction was performed using the SALSA MS-MLPA
Reagents kit (MRC-Holland, The Netherlands), following a
custom-modified MS-MLPA standard reaction protocol. We
used 80–110 ng of DNA sample, and the ligation/digestion
reactionwasperformedwith0.75μlo fHhaIenzyme(Promega
R6441, 10 U/μl) for 50 min at 49°C. Finally, 24 cycles were
used in PCR reaction. All other conditions were as detailed in
MRC-Holland instructions.
Methylation dosage ratio was obtained by the following
calculation: Dm0(Px/Pctrl)Dig/(Px/Pctrl)Undig, where Dm is the
methylation dosage ratio, Px is the peak area of the given
probe, Pctrl is the sum of the peak area of all control probes,
Dig stands for HhaI digested sample, and Undig stands for
the undigested sample. Dm can vary between 0 and 1.0
(corresponding to 0–100% of methylated DNA).
LINE-1 methylation analysis by COBRA
LINE-1 promoter methylation was investigated by a modified
COBRA PCR protocol reported by Chalitchagorn et al. [24].
DNAwas first modified using the CpGenome DNA Modifica-
tion Kit (Chemicon, Temecula, CA, USA) and the bisulfite
converted DNA was subjected to 35 cycles of PCR with two
828 J Mol Med (2012) 90:827–835primers, 5′-GCGTAAGGGGTTAGGGAGTTTTT-3′ and 5′-
RTAAAACCCTCCRAACCAAATATAAA-3′,w i t ha n
annealing temperature of 50°C. The amplicons were digested
in 15 μl reaction volume with 20 U of TaqI or 10 U of TasI in
1× corresponding enzyme buffer (MBI Fermentas, USA) at
65°C for 6 h. The digested PCR products were electrophoresed
in 4.5% NuSieve 3:1 agarose gels (Cambrex, Iowa, USA).
Intensities of the digested and undigested bands were obtained
by scanning and scoring with NIH Image Software [25].
LINE-1 methylation level was calculated as a percentage of
intensityofTaqIdividedbythesumofTaqI-an dTasI-positive
amplicons. The LINE-1 amplicon size is 160 bp. Methylated
amplicons, TaqI positive, yielded two 80-bp DNA fragments,
whereas unmethylated amplicons, TasI-positive, yielded
63- and 97-bp fragments.
Statistical analysis
Statistical analyses were performed using SPSS Statistics
Software (IBM SPSS, Inc., Chicago, IL, USA). Statistical
significance for the differences between distributions was
evaluated as follows. Depending on whether or not the data
were normally distributed (as evaluated by Shapiro–Wilk
test), a parametric or nonparametric test, respectively, was
chosen. For pairwise analysis of correlated samples (intra-
group comparisons), t test (parametric) or Wilcoxon signed
rank test (nonparametric) was used. To evaluate the signif-
icance of difference between the means of two independent
groups (inter-group comparisons), t test (parametric) or
Mann–Whitney U test (nonparametric) was applied. For
the comparison of multiple (≥3) independent groups with
normally distributed data, we used one-way ANOVA (or
Welch test when the assumption of homogeneity of variances,
as evaluatedbyLevene’s test, was notmet). This wasfollowed
by an appropriate post hoc test (in our case, Games–Howell
testashomogeneityofvarianceswasnotfulfilled)todetermine
which particular groups differed. For correlations, the Pearson
product-moment correlation coefficient (r) for linear correla-
tionwasdeterminedforparametricdataandtheSpearmanrank
correlation coefficient (rho) for nonparametric data. P’s<0.05
(two-tailed) were considered significant.
Results
MS-MLPA assay design
A custom-made MS-MLPA assay was designed as described
in “Materials and methods” to monitor the methylation status
of three HhaI sites (with the respective probe pairs designated
as 1m, 2m, and 3m) inside the LINE-1 promoter sequence
(Fig. 1). Representative images from MS-MLPA analysis are
shown in Fig. 2a. Dm values obtained with the three different
probe pairs were highly concordant with each other (P<0.001
by Pearson correlation analysis for the entire sample series).
All results below will be given using 2m probes because the
sameregionwasincludedinmostassaysdevelopedtodatefor
LINE-1 methylation studies (e.g., COBRA assay used by
Chalitchagorn et al. [24], and pyrosequencing assay used by
Goel et al. [14], see Fig. 1). Evaluation of cell lines and other
test samples revealed a good correlation (P<0.001) between
Dm values obtained by MS-MLPA and the fraction of meth-
ylated LINE-1 sequences obtained by COBRA (Fig. 2b). The
same was true for patient specimens (Supplementary Fig. 1).
In studies on patient specimens, a whole genome amplified
DNA and a cell line DNA with a known Dm value were
included in each assay to assess HhaI cleavage and reproduc-
ibility, respectively.
Table 1 Description of the study series
Colorectal cancer Gastric cancer Endometrial
cancer
Sporadic
CRC MSS
Sporadic
CRC MSI
Lynch–
CRC
FCCX Sporadic
GC MSS
Sporadic
GC MSI
Lynch–
GC
Lynch–EC
Total number of tumors 55 52 43 18 34 11 13 50
Mean age of diagnosis (years) 70.3 73.5 45.7 56.4 71.1 76.5 57.5 49.9
Germline mutation in MMR genes (total) N/A N/A
a 43 0 N/A N/A
a 13 50
MLH1 38 11 41
MSH2 52 4
MSH6 00 5
MSI–high 0 14 40 1 0 11 13 33
b
N/A not applicable
aDue to MLH1 promoter methylation in most cases.
bIn the same series, MMR protein corresponding to the germline mutation was lost in 36/36, 100%, cases available for immunohistochemical
analysis
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830 J Mol Med (2012) 90:827–835LINE-1 methylation in normal vs. tumor tissues: intra-group
comparison
We studied 276 cancer specimens and paired normal tissues
(representing colorectal mucosa, gastric mucosa, or endome-
trium) from individuals with familial/hereditary or sporadic
cancers, divided into eight groups (Fig. 3, Supplementary
Table 1, Supplementary Fig. 2). In all groups, the average
LINE-1 methylation dosage ratio was lower in tumor DNA
relative to normal DNA, and the degree of hypomethylation
reached statistical significance in most groups (denoted by
asterisks in Fig. 3). In individuals from whom three different
typesoftissueswereavailable(Fig.4,SupplementaryTable2,
Supplementary Fig. 3), LINE-1 methylation showed a tissue-
specific pattern with the highest level in blood, followed by
normal epithelium, and the lowest level in tumors.
LINE-1 methylation in normal and tumor tissues
from different patient groups: inter-group comparison
One-way ANOVA analysis of the eight tumor groups shown
inFig.3indicatedastatisticallysignificantdifferencebetween
groups (P<0.001). Among CRC tumors, the average LINE-1
methylation dosage ratio (from the highest to the lowest) was
0.87 for sporadic MSI-CRC, 0.85 for sporadic MSS-CRC,
0.84 for LS-CRC, and 0.80 for FCCX (the difference was
statisticallysignificantbetweenthefirstandthelastgroup,P0
0.042 by the Games–Howell post hoc test; Fig. 3). The results
suggest that LINE-1 methylation in CRCs depended on MSI
statusandpatientcategory.AmongGCtumors,LINE-1meth-
ylation was 0.88 for sporadic MSI-GC, 0.86 for LS-GC, and
0.79 for sporadic MSS-GC (the difference was statistically
significant between the first and the last group, P00.018).
Furthermore, while LS-GC and sporadic MSI-GC were all of
intestinalhistology, MSS-GCconsisted oftumorswithdiffuse
vs. intestinal histology, and the average LINE-1 methylation
was significantly higher in diffuse tumors (0.85 vs. 0.74, P0
0 . 0 0 5b yt w o - t a i l e dt test). Our results suggest that MSI
status and histology influenced LINE-1 methylation in
GC.
There was also a statistically significant difference between
thenormaltissuegroupsshowninFig.3(P<0.001byone-way
ANOVA). In particular, normal mucosa tissues from CRC
patients showed a declining trend in the average LINE-1 meth-
ylation as follows: sporadic MSS-CRC (0.93), sporadic MSI-
CRC (0.91), LS-CRC (0.90), and FCCX (0.84). The Games–
Howell post hoc test indicated a statistically significant differ-
ence between FCCX with the lowest LINE-1 methylation in
normal mucosa and any other group (at the level of P<0.05or
at higher significance levels) and between sporadic MSS-CRC
and LS-CRC (P00.038). The findings suggest that LINE-1
methylation signatures in normal mucosa varied according to
the specific groups of CRC patients they represented. Further-
more, LINE-1 methylation was lower in all three tissues
(blood, normal mucosa, and tumor) from patients with FCCX
compared to the respective tissues from patients with LS-CRC
(the difference reached statistical significance between normal
mucosa samples, P00.018, by t test, and between blood sam-
ples,P00.020,byMann–WhitneyUtest;Fig.4).Therewasno
correlation between LINE-1 methylation in normal mucosa or
blood and the age of the patients (data not shown).
LINE-1 methylation vs. tumor suppressor gene methylation
Tumor suppressor gene (TSG) methylation data for the
present patient groups were mainly available from our
Fig. 1 Diagram of the CpG island promoter (GenBank accession no.
M80343, nucleotide position 108-520 bp) associated with the full
length LINE-1. The 5´UTR, 3´UTR and two open reading frames
(ORF) of LINE-1 are shown. Location of all ten probe pairs included
in the present MS-MLPA assay are indicated below the LINE-1 bar by
black/grey and black squares (the so-called L1-m and control probes,
respectively). Single CpG sites in the region containing the L1-m
probes are shown by vertical lines in the lower part of the diagram.
Numbered arrows indicate the location of primers: 1- used for bisulfite
PCR in COBRA assay [in the present work and by Chalitchagorn et al.
[24], see “Materials and methods”]; 2- used for pyrosequencing by
Goel et al. [14]. The exact CpG sites that are part of HhaI recognition
sequences in the three L1-m probes as well as the two CpG sites
recognized by restriction enzymes used in COBRA are shown by thick
vertical lines. LPO and RPO denote sequences homologous to LINE-1
and correspond to the underlined sequences in Table 2
J Mol Med (2012) 90:827–835 831earlier studies, and Supplementary Table 1 gives the average
number of methylated TSGs (out of 24 studied) against
LINE-1 methylation results. As evident from Supplementa-
ry Table 1, LINE-1 methylation was able to distinguish
tumor from normal tissue in some groups where TSG meth-
ylation could not (e.g., sporadic MSS-GC). In case-by-case
analysis by the Pearson test, TSG methylation did not cor-
relate with LINE-1 methylation in tumors from any of the
eight patient groups, with a single exception (inverse corre-
lation in LS-EC, P00.027).
Discussion
CRC provides a useful model to study multistep tumorigen-
esis and the role that DNA methylation plays therein [26]. In
sporadic colorectal tumors, genetic instability in the form of
CIN or MSI and epigenetic instability in the form of CIMP
overlap, resulting in at least three subsets with distinct
clinicopathologic features: CIMP+/MSI+, CIMP+/MSI-,
CIMP-/CIN [27]. LINE-1 hypomethylation has been
reported to be positively associated with CIN [13, 25] and
inversely with MSI [13, 25, 28, 29]. Among the present
sporadic cancers, MSS-CRC and MSS-GC had lower LINE-
1 values than the respective MSI cancers (the difference was
statistically significant among GC) in accordance with
reported studies. Variable correlations of LINE-1 hypome-
thylation with CIMP have been observed in CRC, including
inverse association [13, 29] and no association [28]. In our
study, LINE-1 hypomethylation did not correlate with TSG
methylator phenotype in CRC. Such seemingly inconsistent
observations may be reconciled when the basic mechanisms
of LINE-1 hypomethylation [30] and CIMP [31, 32], which
are largely unknown at present, become better understood.
The overall degree and patterns of DNA methylation tend
to be tissue-specific, as shown by studies of CpG islands
Fig. 2 a, LINE-1 CpG island
promoter methylation analysis
by custom-made MS-MLPA
kit. Results from an unmethy-
lated sample (WGA) and a
methylated sample (FFPE
tumor DNA) are shown. Peaks
specific to L1-m probes are
indicated by arrowheads and
the respective Dm values are
boxed. Peaks without a label
correspond to control probes. b,
Graphical comparison of results
from LINE-1 promoter
methylation analysis by
MS-MLPA (Dm, Y- axis) and
COBRA (fraction of methylated
LINE-1 sequences, X - axis)
revealed a good correlation as
indicated by the Pearson test
832 J Mol Med (2012) 90:827–835and CpG island “shores” [33], global 5-methylcytosine con-
tent [22], and LINE-1 methylation [24]. LINE-1 methylation
generally correlates with global genomic 5-methylcytosine
content [22, 34]. An important finding in the present inves-
tigation was that even within a given tissue, notably normal
colorectal mucosa from patients with CRC, the degree of
LINE-1 methylation varied according to the patient category
and showed a decreasing trend from sporadic MSS-CRC to
sporadic MSI-CRC to LS-CRC to FCCX. A few previous
reports exist of DNA methylation in normal colorectal
mucosa being associated with pathway-specific predisposi-
tion to cancer. Using the MLH1 and CALC1 genes as indi-
cators for methylation, we previously showed that the
absence vs. presence of methylation distinguished colonic
mucosa in individuals who developed MSI (+) and MSI (−)
tumors, respectively [35]. Studies on individuals undergoing
colonoscopy for various reasons revealed that age-related
(“type A” [36]) methylation in normal mucosa was inversely
associated with colorectal adenomas, the precursors of CIN
cancers, whereas CIMP (“type C” methylation) was
Fig. 3 Average methylation
dosage ratio±one standard
deviation for LINE-1 in tumor
(T) vs. normal (N) tissues. The
results are given separately for
each patient category out of
8 (listed in the key). Please see
Supplementary Table 1 for the
exact numerical values and
Supplementary Fig. 2 for the
relationship between T and N
case by case. Asterisks indicate
statistical significance for the
differences between T and N
within each patient category
(intra-group comparison) on the
level of P<0.05 (*), P<0.01
(**), and P<0.001 (***)
Fig. 4 Average methylation
dosage ratio±one standard
deviation for LINE-1 in tumor
(T) vs. normal colorectal
mucosa or endometrium (N) vs.
blood (B) from patients with T,
N, and B available. Please see
Supplementary Table 2 for the
exact numerical values and
Supplementary Fig. 3 for the
relationship between T and N
case by case. Asterisks indicate
statistical significance for the
differences in pairwise
comparisons of T, N, and B
within each patient category
(intra-group comparison) on the
level of P<0.01 (**) and P<
0.001 (***) (-, nonsignificant)
J Mol Med (2012) 90:827–835 833significantly associated with advanced proximal serrated
polyps, the precursors of CIMP cancers [37]. However, the
latter investigation found no association between LINE-1
methylation status in normal mucosa and subsequent colo-
rectal pathology.
The existing data on LINE-1 hypomethylation in famil-
ial/hereditary cancer are scarce. Goel et al. [14] showed that
CRCs from FCCX displayed a significantly lower degree of
LINE-1 methylation than CRCs from LS or sporadic MSI or
MSS cases; results from the corresponding normal tissues
were not reported. Among CRCs from our series, too,
FCCX showed the lowest mean degree of LINE-1 methyl-
ation, further supporting the notion from Goel et al. [14] that
LINE-1 methylation is indeed one of the few distinguishing
features of FCCX known to date. Nevertheless, the most
dramatic differences in our investigation were seen between
tissues of normal mucosa from the different patient catego-
ries. The patient category seemed to be even more important
than tissue type in determining the degree of LINE-1 meth-
ylation in normal samples. Apart from the category-specific
variation in normal mucosa specimens from CRC patients
(see above), all three normal tissues investigated from LS
patients (colorectal mucosa, gastric mucosa, and endometri-
um) and also blood from LS patients with CRC vs. EC
showed comparable levels of LINE-1 methylation (Figs. 3
and 4).
FFPE samples stored in pathology archives represent a
major source of patient specimens that may remain in part
unused because of the lack of methods that take into account
the often lower quality and quantity of the extracted DNA.
Common methods to study LINE-1 methylation include
COBRA [25], MethyLight [22], and pyrosequencing [28].
While these techniques have been applied to FFPE samples
as well, all rely on bisulfite conversion and require relatively
large amounts of template DNA. We, therefore, took an
alternative approach and developed MS-MLPA-based
assays that do not require bisulfite conversion, work with
limited amounts of template DNA, and allow multiplexed
reactions for studies of several regions of LINE-1 simulta-
neously. While the percentages of LINE-1 methylation re-
flect the basic technique and the method of calculation used,
we demonstrated that our MS-MLPA results were well in
line with those obtained with COBRA. Given the increasing
evidence of the importance of LINE-1 methylation in cancer
and the emerging clinical implications [29], the present
assays and findings are likely to stimulate future studies in
this field.
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